Dysautonomia Center Research
The research team at NYU Langone’s Dysautonomia Center, led by Horacio Kaufmann, MD, and Lucy J. Norcliffe-Kaufmann, PhD, has made a number of discoveries that have changed our understanding of autonomic disorders and brought new treatment options to people living with autonomic dysfunction. Our primary focus is on neurological conditions that affect the autonomic nervous system. We also translate laboratory findings into specific treatments for autonomic disorders. Learn more about our clinical trials.
The Dysautonomia Center is the leading site for research on and treatment of familial dysautonomia (FD). Our research program is supported by the Dysautonomia Foundation, Inc., and we receive grant funding from the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and The Michael J. Fox Foundation.
Our research team includes scientists and physician–scientists who have diverse backgrounds in physiology, neurology, sleep medicine, movement disorders, medicine, and psychiatry. Our team also includes research coordinators, project assistants, and data managers who manage databases and project logistics.
Dysautonomia Center Discoveries
The Dysautonomia Center has made important key discoveries that have shaped our understanding of autonomic neurology and have helped bring new treatments to the clinic. These include the following:
- the first neuropathological studies on FD that describe the loss of sensory nerves
- the first complete neuropathological description of pure autonomic failure, showing Lewy bodies in the peripheral autonomic nerves
- the first neuropathological description of patients with Lewy body synucleinopathies presenting with long-standing isolated autonomic failure
- the first reported evidence of end-organ target damage as a consequence of supine hypertension in patients with autonomic failure
- a comprehensive study of the vasoactive peptides endothelin, atrial natriuretic peptide, and vasopressin in autonomic synucleinopathies
- a description of the clinical features of FD and the impact of therapeutic interventions
- seminal trials of midodrine and droxidopa, the two drugs primarily used in the treatment of chronic orthostatic hypotension caused by autonomic failure
- a therapeutic trial of midodrine for the treatment of orthostatic hypotension in patients with FD
- use of fundoplication to prevent aspiration pneumonia, leading to a dramatic increase in life expectancy in patients with FD
- a brain MRI–based algorithm for the differential diagnosis of Parkinson’s disease and multiple system atrophy
- therapeutic trials of botulinum toxin type A in primary palmar hyperhidrosis and the first description of “subclinical” muscle weakness in the hand
- the first complete description of a vestibular autonomic reflex in humans
- identification of the mutation responsible for FD, in collaboration with Harvard University researchers
- the discovery that the nutritional supplement kinetin corrects the mis-splicing defect responsible for FD
- a study of adaptation to high altitude in Peruvian mountain dwellers
- a report of the effect of water in improving blood pressure control
- the discovery of the role of vascular sensitivity to hyperventilation in susceptibility to vasovagal syncope
- the first study describing FD as a disease of afferent baroreflex failure
- a description of the neurochemical basis for hypertensive vomiting attacks in FD
- a description of the neurohormonal and autonomic profile during seizures in children with benign childhood autonomic seizures (Panayiotopoulos syndrome)
- the first placebo-controlled, randomized clinical trial in FD showing that carbidopa relieves nausea
- a description of the lack of proprioception in FD as a cause of gait ataxia
- a description of optic neuropathy and progressive neuronal loss in the retinal nerve fiber layer in patients with FD
- the first study in humans demonstrating that a nutritional supplement can reverse the gene deficit in FD and has potential as a gene therapy
- a description of cardiac sympathetic denervation in a rare genetic form of Parkinson’s disease
- development and validation of the Orthostatic Hypotension Questionnaire to measure symptoms and monitor the efficacy of therapies
- the description of the natural history of patients with pure autonomic failure
- the description of retinal abnormalities in patients with multiple system atrophy
- the discovery and characterization of retinal pathology in patients with FD
- the unraveling of risk factors for sudden death in patients with FD
- the definition of orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies
Because the autonomic nervous system innervates all organs of the body, we collaborate with a number of specialists in a multidisciplinary approach. We work with experts across NYU Langone in our research and clinical trials. Collaborators include Stuart D. Katz, MD; Harmony R. Reynolds, MD; and Howard Trachtman, MD.
Collaborators outside of NYU Langone include the following:
- Susan Slaugenhaupt, PhD, professor of neurology (genetics) at Harvard Medical School
- Joel G. Gutierrez, MD, professor of neurology and clinical neurophysiology at Havana Medical School
- Vaughan Macefield, PhD, professor of physiology at Western Sydney University
- Frances Lefcort, PhD, professor of neurosciences at Montana State University
Autonomic Disorders Consortium
The Dysautonomia Center is a member of the Autonomic Disorders Consortium, an NIH-funded initiative to bring new therapies to patients with rare autonomic disorders. The center was a founding member of the Autonomic Disorders Consortium, which brings together expert sites in a collaborative effort. The center leads the international natural history study of synucleinopathies, which aims to better understand the autonomic features of Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy and how to diagnose these diseases in the earliest stages, when there is the best chance of preserving function. Investigators at the Dysautonomia Center are focused on defining the natural history of pure autonomic failure, which is a rare condition characterized by neurological damage that affects the control of blood pressure.
Founded in 2009, the Autonomic Disorders Consortium connects patient support groups with physicians and investigators in the medical centers where these patients are cared for, in order to discover ways to treat and cure these disorders.